NCT03537833View on ClinicalTrials.gov

Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed

CompletedOBSERVATIONAL
Enrollment

172

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

February 18, 2021

Study Completion Date

February 11, 2022

Conditions
Patients With Non-small Cell Lung Cancer (NSCLC) and Pleural Mesothelioma and Treated With a Pemetrexed-based Chemotherapy
Interventions
OTHER

pemetrexed-related hematological toxicity

hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria

Trial Locations (1)

51092

Chu Reims, Reims

All Listed Sponsors
lead

CHU de Reims

OTHER

NCT03537833 - Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed | Biotech Hunter | Biotech Hunter